Oct 2022 $7 M No. 4 $2 to $10 million 23
ProMIS Neurosciences Inc.: Raise no. 4, Oct 2022 × Investors in this round 23 investors had bought by the notice of Oct 21, 2022: 23 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for ProMIS Neurosciences Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $7 M of $10 M offered; $3 M still to sell
Smallest investment taken $27,000
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them, other: Each unit consists of one common share and one-quarter of one common share purchase warrant. Each full warrant is exercisable for one common share at an exercise price of $7.50 per common share starti Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last more than a year
Issuer's revenue No revenue
Sales commissions $597,783
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions as estimates
The company Corporation, incorporated in Canada (Federal Level) People named in the notice Daniel T. Geffken · Executive Officer Gail M. Farfel · Executive Officer Gavin T. Malenfant · Executive Officer Larry M. Altstiel · Executive Officer Neil M. Cashman · Executive Officer, Director Eugene T. Williams · Director Josh T. Mandel-Brehm · Director Maggie T. Shafmaster · Director Neil K. Warma · Director Patrick T. Kirwin · Director Richard T. Gregory · Director William K. Wyman · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round CEROS FINANCIAL SERVICES, INC. (CRD 37869) · Rockville, Maryland Sold in CA, CO, FL, IL, MA, NH, NJ, NV, NY, TX, VA, VT Remarks in the notice On fees: “Compensation also includes warrants to purchase 69,188 common shares at $6.10 per share exercisable April 11, 2023 until April 11, 2028, and legal fees of $80,000.”On the amounts: “The additional $2,594,541.00 may be received upon the exercise of share purchase warrants sold inside or outside the U.S.”On the use of proceeds: “In the ordinary course of business, the issuer may use some of the proceeds of the offering to pay salaries to certain of its executive officers and directors.”Signed by Gail M. Farfel, Chief Executive Officer. Source: SEC Form D, newest notice filed Oct 21, 2022. Read the notice at the SEC .
equity, options SEC Aug 2021 $18 M No. 3 $10 to $50 million 34
ProMIS Neurosciences Inc.: Raise no. 3, Aug 2021 × Investors in this round 34 investors had bought by the notice of Sep 9, 2021: 34 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for ProMIS Neurosciences Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $18 M of $25 M offered; $7 M still to sell
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them, other: Each unit consists of one common share and one quarter of one common share purchase warrant. Each whole warrant is exercisable for one common share at an exercise price of $0.21 per common share until Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last more than a year
Issuer's revenue No revenue
Sales commissions $12,674,900
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions as estimates
The company Corporation, incorporated in Canada (Federal Level) People named in the notice Daniel Geffken · Executive Officer Elliot Goldstein · Executive Officer Eugene Williams · Executive Officer, Director Johanne Kaplan · Executive Officer Neil Cashman · Executive Officer, Director Patrick Kirwin · Director Richard Gregory · Director William Wyman · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Ceros Financial Services, Inc. (CRD 37869) · Rockville, Maryland Sold in CA, FL, ID, IL, MA, NH, NJ, NV, NY, PA, TX Remarks in the notice On fees: “Includes 7,921,813 compensation warrants to purchase one common share of common stock at a price of $0.16 per share at any time for up to 5 years.”On the amounts: “The additional $6,603,516.00 may be received upon the exercise of share purchase warrants sold inside or outside the U.S.”On the use of proceeds: “In the ordinary course of business, the issuer may use some of the proceeds of the offering to pay salaries to certain of its executive officers and directors.”Signed by Elliot Goldstein, Ceo. Source: SEC Form D, newest notice filed Sep 9, 2021. Read the notice at the SEC .
equity, options SEC Mar 2021 $7 M No. 2 $2 to $10 million 7
ProMIS Neurosciences Inc.: Raise no. 2, Mar 2021 × Investors in this round 7 investors had bought by the notice of Mar 30, 2021: 7 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for ProMIS Neurosciences Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $7 M of $7 M offered
Smallest investment taken no minimum stated
What was sold equity, debt, options or other rights to buy securities, securities to be acquired by exercising them, other: 1% convertible debentures, payable annually. The Convertible Debentures will mature on March 22, 2026 and are convertible into shares at US$0.10 per share. Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Canada (Federal Level) People named in the notice Daniel E. Geffken · Executive Officer Elliot Goldstein · Executive Officer, Director Eugene Williams · Executive Officer, Director Johanne Kaplan · Executive Officer Neil Cashman · Executive Officer, Director Steven Plotkin · Executive Officer Patrick Kirwin · Director Richard Gregory · Director William Wyman · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “Total Offering Amount represents principal amount of US$7,000,000 convertible debentures. There is no guarantee that the convertible debentures will be converted into shares.”Signed by Elliot Goldstein, CEO and President. Source: SEC Form D, newest notice filed Mar 30, 2021. Read the notice at the SEC .
equity, debt, options SEC Apr 2018 $2 M No. 1 Under $2 million 18
ProMIS Neurosciences Inc.: Raise no. 1, Apr 2018 × Investors in this round 18 investors had bought by the notice of May 3, 2018: 18 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for ProMIS Neurosciences Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $2 M of $3 M offered; $1 M still to sell
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them, other: 5,783,861 Units at US$0.30 per Unit (comprised of one common share and one-half of one common share purchase warrant, exercisable into a share at C$0.48 until April 30, 2023, subject to acceleration) Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last more than a year
Issuer's revenue Not disclosed
Sales commissions $64,761
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions as estimates
The company Corporation, incorporated in Canada (Federal Level) People named in the notice Daniel E. Geffken · Executive Officer Elliot Goldstein · Executive Officer, Director Eugene Williams · Executive Officer, Director Johanne Kaplan · Executive Officer Neil Cashman · Executive Officer, Director Anthony Giovinazzo · Director Johannes Roth · Director Patrick Kirwin · Director Richard Gregory · Director William Wyman · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Noble Capital Markets, Inc. (CRD 15768) · Boca Raton, Florida Sold in FL, NJ, NV Remarks in the notice On fees: “Placement fees of US$64,761 representing 7% of the gross proceeds from the sale of Units to investors introduced by Noble Capital Markets Inc., which also received 215,871 warrants, exercisable at C$0.48 per share for five years.”On the amounts: “Offering Amount equals price of Units(5783861 x US$0.3(C$0.375)/unit) plus exercise price of underlying Warrants(2891926 x C$0.48(US$0.384)/share).No guarantee that the Warrants, expiring 4/30/2023, will be exercised. Based on exchange rate of US$1:C$1.25”Signed by Elliot Goldstein, CEO and President. Source: SEC Form D, newest notice filed May 3, 2018. Read the notice at the SEC .
equity, options SEC